The global ITP therapeutics market was valued at USD 750.12 Million in 2025 and is expected to grow at a CAGR of 5.50%, reaching USD 1281.31 Million by 2035. The market growth is driven by rising aging populations, better disease recognition, and an increase in autoimmune conditions. The use of advanced diagnostics like flow cytometry, PCR, genetic testing also supports market value by offering accurate and early ITP detection, and allowing tailored treatment strategies.
Base Year
Historical Period
Forecast Period
In December 2024, rilzabrutinib showed significant efficacy and safety in the phase 3 LUNA 3 study for chronic ITP, achieving durable platelet responses and reduced bleeding, potentially accelerating market growth by expanding treatment options.
One of the major market trends includes the development of oral Syk inhibitors for ITP treatment. For instance, in January 2024, HUTCHMED’s sovleplenib NDA was accepted with priority review in China, targeting adults with primary ITP.
The market is experiencing steady growth, driven by key players’ focus on innovative oral and targeted therapies, strategic expansions, and enhanced patient access, collectively accelerating market adoption and treatment advancements
Compound Annual Growth Rate
5.5%
Value in USD Million
2026-2035
*this image is indicative*
The market is witnessing significant growth driven by increasing disease prevalence, advances in targeted therapies, and expanding treatment options. ITP, an autoimmune disorder characterized by low platelet counts and heightened bleeding risk, has traditionally been managed with corticosteroids and immunoglobulins. However, the emergence of thrombopoietin receptor agonists (TPO-RAs), targeted biologics, and novel small molecules is reshaping the treatment landscape. Favorable regulatory designations, improved reimbursement frameworks, and expanding research into next-generation therapies such as SYK and BTK inhibitors are further accelerating market expansion.
Rising Prevalence of ITP to Elevate the Growth of the Market
The growing prevalence of immune thrombocytopenia (ITP) worldwide is a significant driver of the market. As an autoimmune disorder characterized by a reduction in platelet count, ITP affects both children and adults, with adult women exhibiting higher incidence rates, particularly those aged 60–84 years. According to Mohamed Amine Bekadja et al., 2025, studies from the United Kingdom, France, Taiwan, and Korea reported incidence rates ranging from 3.03–6.0 per 100,000 person-years in women and 2.3–4.5 per 100,000 person-years in men. The increasing patient population is expected to fuel demand for innovative therapies, supporting sustained market growth.
The market is experiencing key trends, including the increasing adoption of FcRn-targeted therapies and the emergence of BTK inhibitors.
Rising Adoption of FcRn-Targeted Therapies to Boost the Market Growth
The market is witnessing significant momentum with the increasing adoption of FcRn-targeted therapies that address the underlying autoimmune mechanisms of the disease. In March 2024, Argenx received regulatory approval in Japan for VYVGART® (efgartigimod alfa) as a treatment for adults with primary ITP, marking a key milestone in precision medicine for this patient population. This trend highlights a shift toward targeted, biologic-based interventions, enhancing efficacy and safety profiles compared to conventional therapies. Such advancements are expected to bolster market growth over the forecast period.
Emerging BTK Inhibitors Likely to Boost ITP Therapeutics Market Demand
The market is shifting towards targeted oral therapies that address both platelet deficiencies and quality-of-life concerns. In December 2024, the LUNA 3 study highlighted rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, which demonstrated rapid and durable platelet responses, reduced bleeding episodes, and improved patient fatigue levels. The therapy also minimized reliance on emergency interventions and long-term steroid use. This trend toward innovative, well-tolerated treatments is expected to enhance market expansion and drive sustained growth in the ITP therapeutics sector.
Corticosteroids to Lead the Market by Treatment
Corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, thrombopoietin receptor agonists (TPO-RA), and other therapies form the treatment landscape for ITP. Among these, corticosteroids remain a cornerstone due to their rapid effectiveness in elevating platelet counts and controlling acute bleeding episodes. They are especially preferred for newly diagnosed patients, offering a well-established safety profile, cost-effectiveness, and ease of administration. Despite emerging therapies, such as thrombopoietin receptor agonists, corticosteroids continue to maintain strong demand. For instance, in August 2025, Novartis reported positive Phase III results for ianalumab plus eltrombopag, highlighting innovation in TPO-RA therapies. Overall, corticosteroids are expected to remain a fundamental option in ITP treatment strategies.
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these regions, North America is expected to dominate the market, driven by a strong healthcare infrastructure, rapid adoption of novel therapies, and a robust pipeline of innovative treatments. Notably, in July 2025, Sobi North America announced U.S. FDA approval of Doptelet® (avatrombopag) for pediatric patients aged one year and older with persistent or chronic ITP, highlighting the region’s leadership in advancing ITP care. Overall, North America’s continued innovation and strategic focus on rare hematologic disorders is set to sustain its market prominence.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Amgen Inc., a leading biotechnology company, develops innovative human therapeutics targeting serious illnesses. In the immune thrombocytopenia (ITP) market, its flagship product, Nplate® (romiplostim), is a thrombopoietin receptor agonist approved for adults and pediatric patients with insufficient response to first-line therapies. The U.S. Food and Drug Administration expanded Nplate’s indication to include earlier treatment in adults, demonstrating sustained platelet responses and remission in clinical studies. Amgen’s active involvement in advancing ITP therapeutics underscores its commitment to improving patient outcomes in this rare blood disorder.
Grifols, S.A., a leading global producer of plasma-derived medicines, is actively involved in the chronic immune thrombocytopenia (ITP) therapeutics market. The company commercializes Tavlesse® (fostamatinib), the first oral SYK inhibitor indicated for adult patients with ITP who are refractory to other treatments. Launched across multiple European countries, including France, Italy, and Spain, Tavlesse® addresses unmet patient needs by reducing platelet destruction and expanding therapeutic options for healthcare professionals. Grifols continues to strengthen its portfolio through innovative in-licensing and research initiatives in ITP and related conditions.
GlaxoSmithKline (GSK) plc, a leading research-based pharmaceutical and healthcare company, is actively involved in the immune thrombocytopenia (ITP) therapeutics market. Its key product, eltrombopag, marketed as Promacta™ in the U.S. and Revolade™ in Europe, has demonstrated significant efficacy in pediatric patients with chronic ITP, as highlighted in the Phase III PETIT2 study. The therapy improved platelet counts and functional outcomes, addressing unmet needs in patients who failed standard treatments. GSK continues to advance eltrombopag through regulatory submissions, strengthening its position in the ITP therapeutics market.
CSL Behring is a global biopharmaceutical company specializing in immunodeficiency and autoimmune diseases. In the context of the Global ITP Therapeutics Market, the company provides immunoglobulin therapies designed to increase platelet counts in patients with idiopathic thrombocytopenic purpura (ITP). These therapies address symptoms such as bruising, skin discoloration, nosebleeds, and bleeding gums, highlighting CSL Behring’s active role in advancing ITP treatment solutions worldwide.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include F. Hoffmann La Roche, Shangxian Minimal Invassive Inc., Baxter AG, and Novartis AG.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share